These findings suggested that the Aurora-A-regulated cytosolic localization of Maf1 contributes to tumor progression; in HCC patients with high expression of both Aurora-A and Maf1, targeting Aurora-A could be a promising therapeutic strategy for cancer treatment. This evidence concerns the gene MAF1 and neoplasm.